Phase I dose escalation study of lestaurtinib in patients with myelofibrosis

Despite extensive prior clinical investigation in acute leukemia (60 – 100 mg), dose finding studies have not yet established a true maximum tolerated dose (MTD) for the oral multi-kinase inhibitor lestaurtinib in hematologic malignancies. We performed a multicenter, investigator initiated, phase I...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Leuk Lymphoma
Autori principali: Hexner, Elizabeth O, Mascarenhas J, John, Prchal, Josef, Roboz, Gail J, Baer, Maria R, Ritchie, Ellen K, Leibowitz, David, Demakos, Erin P, Miller, Crystal, Siuty, James, Kleczko, Jill, Price, Leah, Jeschke, Grace, Weinberg, Rona, Basu T, Titiksha, Pahl, Heike L, Orazi, Attilio, Najfeld, Vesna, Marchioli, Roberto, Goldberg, Judith D, Silverman, Lewis R, Hoffman, Ronald
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2015
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5665563/
https://ncbi.nlm.nih.gov/pubmed/25563429
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2014.1001986
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi